1. Metabolic Disease

Metabolic Disease

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-30008
    Cycloleucine 52-52-8 ≥98.0%
    Cycloleucine is a specific inhibitor of S-adenosyl-methionine mediated methylation. Cycloleucine is antagonist of NMDA receptor associated glycine receptor, with a Ki of 600 μM. Cycloleucine is also a competitive inhibitor of ATP: L-methionine-S-adenosyl transferase in vitro. Cycloleucine has anxiolytic and cytostatic effects.
    Cycloleucine
  • HY-154629
    Sesame Oil 8008-74-0 ≥98.0%
    Sesame Oil is a vegetable oil. Sesame Oil can be extracted from the seeds of Sesamum indicum L. Sesame Oil decreases NF-κB, aspartate aminotransferase, alanine aminotransferase, IL-1β, IL-4 and nitric oxide. Sesame Oil has antitumor activity against malignant melanoma. Sesame Oil has protective effects against liver damage caused by various agents such as Cisplatin (HY-17394) and Acetaminophen (HY-66005). Sesame Oil shows antinociceptive and anti-inflammatory activities.
    Sesame Oil
  • HY-101455
    CDN1163 892711-75-0 99.90%
    CDN1163 is an allosteric sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activator that improves Ca2+ homeostasis. CDN1163 attenuates diabetes and metabolic disorders.
    CDN1163
  • HY-130705A
    Tachysterol 3 17592-07-3 99.68%
    Tachysterol 3 is a photoproduct of Previtamin D3 (HY-130705).
    Tachysterol 3
  • HY-B1068
    Tyloxapol 25301-02-4
    Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surface active stabilizer. Tyloxapol is used to induce hyperlipidemia in animals.
    Tyloxapol
  • HY-100111
    GLX351322 835598-94-2 99.48%
    GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.
    GLX351322
  • HY-17408
    Mevastatin 73573-88-3 99.46%
    Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment.
    Mevastatin
  • HY-110063
    4-IPP 41270-96-6 99.46%
    4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).
    4-IPP
  • HY-14415
    SR8278 1254944-66-5 ≥98.0%
    SR8278 is a REV-ERBα antagonist and inhibits the REV-ERBα transcriptional repression activity with an EC50 of 0.47 μM. SR8278 is used to regulate the metabolism in organisms and study biological rhythm. SR8278 also can be used for the research of Duchenne muscular dystrophy and Alzheimer's disease.
    SR8278
  • HY-B0135
    Furosemide 54-31-9 99.83%
    Furosemide is a potent and orally active inhibitor of Na+/K+/2Cl- (NKCC) cotransporter, NKCC1 and NKCC2. Furosemide is also a GABAA receptors antagonist and displays 100-fold selectivity for α6-containing receptors than α1-containing receptors. Furosemide acts as a loop diuretic and used for the study of congestive heart failure, hypertension and edema.
    Furosemide
  • HY-113046
    5-Methyltetrahydrofolic acid 134-35-0 99.77%
    5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases.
    5-Methyltetrahydrofolic acid
  • HY-W018392
    Mono-(2-ethylhexyl) phthalate 4376-20-9
    Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD).
    Mono-(2-ethylhexyl) phthalate
  • HY-P0035A
    Insulin solution (human) 11061-68-0
    Insulin solution (human) is a polypeptide hormone that regulates the level of glucose. Insulin solution (human) can be used for the diabetes mellitus.
    Insulin solution (human)
  • HY-A0124A
    Sapropterin dihydrochloride 69056-38-8 ≥98.0%
    Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin also drives autoimmunity. Sapropterin can be used in study of phenylketonuria (PKU).
    Sapropterin dihydrochloride
  • HY-17468
    Bumetanide 28395-03-1 99.95%
    Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
    Bumetanide
  • HY-32351
    Calcifediol 19356-17-3 99.94%
    Calcifediol (25-hydroxy Vitamin D3) is an effective VDR ligand and VD supplement. Calcifediol is a prohormone of the vitamin D endocrine system (VDES) and is hydroxylated in the liver to produce the active form, calcitriol. Calcifediol can rapidly increase serum VD levels.
    Calcifediol
  • HY-A0005
    Clofarabine 123318-82-1 99.88%
    Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit.
    Clofarabine
  • HY-16950A
    (E/Z)-4-Hydroxytamoxifen 68392-35-8 ≥99.0%
    (E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective estrogen receptor modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity.
    (E/Z)-4-Hydroxytamoxifen
  • HY-CP001
    D-Trehalose, Carrier Protein 99-20-7 99.76%
    D-Trehalose is a disaccharide formed by a 1,1-glycosidic bond between two α-glucose units and is widely used as a food ingredient and pharmaceutical excipient. D-Trehalose is known to protect and stabilise proteins. For long-term storage, recombinant protein solution should be diluted further with 5% D-Trehalose, Carrier Protein.
    D-Trehalose, Carrier Protein
  • HY-N0771
    L-Isoleucine 73-32-5
    L-Isoleucine is an orally active branched chain amino acid, which is the L-enantiomer of isoleucine. L-Isoleucine has a role as a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite, a plant metabolite, a human metabolite, an algal metabolite and a mouse metabolite. L-Isoleucine regulates the inflammatory response to protect against pathogens in vivo and in vitro.
    L-Isoleucine
Cat. No. Product Name / Synonyms Application Reactivity